Key result
The R146G troponin I mutation reduced the active M state to 25% of wild-type levels and stabilized the intermediate C state to ~91% of the total actin filaments.
Why the study?
Does the R146G TnI mutation alter the distribution of states of regulated actin at low and high Ca(2+) concentrations compared to wild-type?
Does the R146G TnI mutation alter the distribution of states of regulated actin at low and high Ca(2+) concentrations compared to wild-type?
The R146G troponin I mutation associated with hypertrophic cardiomyopathy stabilizes the intermediate 'C' state of regulated actin, suggesting a novel regulatory interaction in the inhibitory region.
R146G TnI may stabilize the C state in hypertrophic cardiomyopathy; hypothesis-generating and requires human validation before clinical relevance.
The R146G mutation of troponin I (TnI) is associated with hypertrophic cardiomyopathy in humans. Earlier data pointed to stabilization of the intermediate, C state, of actin-tropomyosin-troponin by this mutant. Because cardiac disorders appear to be linked to changes in regulated actin distributions, we determined the extent to which the R146G TnI mutant alters the distribution of states at low and high Ca(2+) concentrations. We show, from measurements of the kcat for actin-activated ATPase activity at saturating Ca(2+) concentrations, that R146G TnI reduced the population of the active, M, state to 25% of the wild-type level. Together with acrylodan-tropomyosin fluorescence measurements of the B state, it appeared that the C state was populated at ∼91% of the total for the R146G TnI-containing actin filaments. The C state was also more heavily populated at low Ca(2+) concentrations. Acrylodan-tropomyosin fluorescence changes showed a large diminution in the inactive state value relative to the wild-type value without a comparable increase in the active state. Furthermore, the rate of binding of rigor S1 to pyrene-labeled actin filaments containing R146G TnI was faster than the rate of binding to wild-type filaments at low free Ca(2+) concentrations. These results indicate that the inhibitory region of TnI affects the B-C and M-C equilibria of actin-tropomyosin-troponin. The observation that a mutation in the inhibitory region affects the M-C equilibrium may point to a novel regulatory interaction.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2016) studied Hypertrophic cardiomyopathy. R146G mutation of troponin I (TnI) vs. Wild-type TnI was evaluated on Distribution of states of actin-tropomyosin-troponin at low and high Ca(2+) concentrations. The R146G troponin I mutation reduced the active M state to 25% of wild-type levels and stabilized the intermediate C state to ~91% of the total actin filaments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: